Skip to main content
Lyra Therapeutics, Inc. logo

Lyra Therapeutics, Inc. — Investor Relations & Filings

Ticker · LYRA ISIN · US55234L1052 US Manufacturing
Open in API
Filings indexed 356 across all filing types
Latest filing 2023-09-01 Regulatory Filings
Country US United States of America
Listing US LYRA

About Lyra Therapeutics, Inc.

https://lyratherapeutics.com/

Lyra Therapeutics, Inc. is a clinical-stage biotechnology company that develops and commercializes innovative therapies for the localized treatment of chronic rhinosinusitis (CRS). The company's product candidates are long-acting, anti-inflammatory sinonasal implants designed to deliver medication directly to sinonasal tissues. This approach aims to provide a new, long-lasting treatment option for patients with this debilitating inflammatory disease, targeting tissues that are not easily accessible with conventional therapeutic methods.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2023-09-01 English
424B5 Filing
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a controlled equity offering of common stock. It details the terms of the offering, the sales agreement with Cantor Fitzgerald & Co., and includes sections such as risk factors, use of proceeds, dividend policy, and plan of distribution. It references registration statements and filings with the SEC but is itself an offering document for new shares. This type of document is a capital raising announcement and update, not a financial report, earnings release, or management discussion. Therefore, it fits the category of Capital/Financing Update (CAP). The document length and content confirm it is not a brief announcement or a regulatory filing fallback. Confidence is high given the clear nature of the document as a prospectus supplement for a stock offering.
2023-09-01 English
SC 13G
Major Shareholding Notification
2023-08-25 English
10-Q Filing
Interim / Quarterly Report Q2 2023
2023-08-08 English
8-K Filing
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2023, reporting the company's financial results for the quarter ended June 30, 2023. It includes a press release as an exhibit announcing these results. The text explicitly states this is a Current Report on Form 8-K, which is used for reporting material events including earnings announcements. The document is relatively short (3634 characters) and primarily contains the announcement of quarterly financial results rather than detailed financial statements or comprehensive analysis. Therefore, it fits the definition of an Earnings Release (ER), which is the initial announcement of quarterly financial results with key highlights only.
2023-08-08 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated July 12, 2023. It reports the entry into a material definitive agreement, specifically the Seventh Amendment to a lease agreement. The content focuses on the lease amendment details and does not contain financial statements or quarterly/yearly financial results. The document length is 4183 characters, which is relatively short and primarily serves as a regulatory announcement of a material event. This fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other specific categories like Annual Report, Earnings Release, or Capital/Financing Update.
2023-07-14 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.